Shareholders that lost money on Kyverna Therapeutics, Inc.(KYTX) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More ...

NEW YORK, Jan. 21, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Kyverna Therapeutics, Inc. ("Kyverna Therapeutics, Inc." or the "Company") (NASDAQ: KYTX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Kyverna Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of all those who purchased or otherwise acquired Kyverna common stock pursuant and/or traceable to the Company's o ...

The Schall Law Firm Invites Shareholders With Losses To Join A Securities Fraud Case Against Kyverna Therapeutics, Inc. ...

Core Viewpoint - A securities class action lawsuit has been filed against Kyverna Therapeutics, Inc. on behalf of investors who purchased its common stock during the February 8, 2024 IPO, with a lead plaintiff deadline set for February 7, 2025 [1]. Group 1: Allegations Against Kyverna - The lawsuit alleges that Kyverna's prospectus and registration statements contained materially false and misleading statements regarding the company's business, operations, and prospects [2]. - Specifically, it is claimed that Kyverna failed to disclose adverse data related to one of its clinical trials at the time of the IPO [2]. Group 2: Lead Plaintiff Process - Investors in Kyverna have until February 7, 2025, to seek appointment as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel [3]. - The lead plaintiff will act on behalf of all class members and typically is the investor or small group of investors with the largest financial interest [3]. Group 3: Firm Information - Kessler Topaz Meltzer & Check, LLP is known for prosecuting class actions and has a reputation for recovering billions of dollars for victims of fraud and corporate misconduct [5]. - The firm encourages Kyverna investors who have suffered significant losses to contact them for more information [4].

Core Viewpoint - Kyverna Therapeutics, Inc. (KYTX) is facing a class action lawsuit, which has been notified to its shareholders by Levi & Korsinsky, indicating potential legal challenges for the company [1] Group 1 - The class action lawsuit is related to allegations against Kyverna Therapeutics, which may impact the company's reputation and financial standing [1] - Shareholders are urged to be aware of an upcoming deadline concerning the lawsuit, emphasizing the importance of timely action [1] - The notification serves as a reminder for investors to stay informed about legal proceedings that could affect their investments in Kyverna Therapeutics [1]

INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Kyverna Therapeutics ...

KYTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Investors of Kyverna Therapeutics, Inc. to Contact the Firm Today! ...

Levi & Korsinsky Notifies Kyverna Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - KYTX ...

NEW YORK, Jan. 17, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) pursuant and/or traceable to Kyverna’s initial public offering conducted on February 8, 2024 (the “IPO”), of the important February 7, 2025 lead plaintiff deadline. SO WHAT: If you purchased Kyverna common stock you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...

Group 1 - The article announces a deadline for joining a class action lawsuit against Kyverna Therapeutics, Inc. (KYTX) [1] - The deadline to join the class action is set for February 7, 2025 [1] - The lawsuit pertains to potential grievances related to Kyverna Therapeutics, Inc. [1]